Autolus Pioneers CAR-T Cell MS Treatment

https://www.youtube.com/watch?v=ZCuv3W2XHCQ

QSA congratulates Autolus for achieving its historic milestone dosing the first patient with its pioneering BOBCAT trial of obecabtagene autoleucel (obe-cel), a ‘one-time’ immunotherapy treatment for progressive multiple sclerosis (PMS). QSA is providing advanced imaging analytics in support of this groundbreakig work.